8-K: Cingulate Announces Positive Safety Data from Phase 3 Trials for ADHD Drug CTx-1301, Eyes FDA Submission

Cingulate Inc. reports positive safety results from Phase 3 trials for CTx-1301, its lead candidate for ADHD treatment, and is on track to file for FDA approval in mid-2025.

Summary

• Cingulate Inc. has announced positive safety results from the final Phase 3 trials for its lead ADHD asset, CTx-1301.
• The company is preparing to file for FDA approval in mid-2025.
• CTx-1301 is a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD.
• The safety data includes results from two Phase 3 pediatric and adolescent studies and a food effect study with healthy adults.
• No subjects experienced a serious treatment emergent adverse event (TEAE), a serious TEAE, or a TEAE leading to death.
• There were no clinically relevant trends in TEAEs overall.
• The pharmacokinetics of the food effect study are being analyzed, but medical findings are consistent with previous studies showing CTx-1301 can be taken with or without food.
• A final analysis combining adult and pediatric safety and efficacy data is expected to be announced mid-2025 and will be included in the NDA submission to the FDA.
• As of March 4, 2025, the company had 3,647,655 shares of its common stock issued and outstanding.

Sentiment

Score: 8

Explanation: The document presents positive safety data and a clear path towards FDA submission, indicating a favorable outlook for Cingulate and CTx-1301. The lack of serious adverse events and the potential for a differentiated product contribute to the positive sentiment.

Positives

• CTx-1301 has demonstrated a consistent and unprecedented safety profile across nine clinical trials.
• The company is on track to file for FDA approval in mid-2025.
• The food effect study suggests CTx-1301 can be taken with or without food.
• CTx-1301 aims to address the unmet need for a true, once-daily ADHD medication, potentially improving adherence and reducing side effects.

Risks

• The FDA may not approve CTx-1301.
• The final analysis combining adult and pediatric safety and efficacy data is still pending.
• The pharmacokinetics of the food effect study are still being analyzed.

Future Outlook

Cingulate anticipates filing a New Drug Application (NDA) with the FDA in mid-2025 for CTx-1301, following a final data analysis and a pre-NDA meeting with the FDA.

Management Comments

• Cingulate Chairman and CEO Shane J. Schaffer stated that the company is pleased with the consistent and unprecedented safety profile of CTx-1301 and looks forward to bringing the first, true, once-daily stimulant medication to market.
• ADHD expert Ann C. Childress, MD, expressed excitement for patients and providers to have CTx-1301 as a treatment option, potentially overcoming unmet needs related to adherence, efficacy, and side effects of existing medications.

Industry Context

The announcement addresses the ongoing need for improved ADHD treatments, particularly those offering true once-daily dosing to enhance patient adherence and reduce the potential for abuse and diversion associated with short-acting stimulants. CTx-1301 aims to compete with existing extended-release stimulant medications by providing a more consistent and longer duration of action.

Comparison to Industry Standards

• Current ADHD treatments often require multiple doses throughout the day, leading to adherence issues and potential for abuse, as highlighted by Dr. Childress.
• Competitors like Shire (now Takeda) with Vyvanse and Janssen with Concerta offer extended-release options, but CTx-1301 aims to differentiate itself with a true once-daily profile and a novel drug delivery platform.
• The absence of serious adverse events in the Phase 3 trials positions CTx-1301 favorably compared to some existing ADHD medications that carry warnings about potential cardiovascular or psychiatric side effects.

Stakeholder Impact

• Positive safety data could lead to increased shareholder value.
• Successful FDA approval would provide a new treatment option for ADHD patients.
• The company's employees are likely to be positively impacted by the progress towards commercialization.

Next Steps

• Cingulate will conduct a final analysis combining adult and pediatric safety and efficacy data.
• The company will hold an in-person Pre-NDA meeting with the FDA on April 2, 2025.
• Cingulate plans to submit a New Drug Application (NDA) to the FDA in mid-2025.

Key Dates